Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keywan Mortezaee

Showing results (51-60 of 142) with videos related to

Pageof 15
Sort By:
ACS Chemical Neuroscience|September 17, 2025
Neurotransmitters in Neural Circuits and Neurological DiseasesAmir Gholami, Keywan Mortezaee
Current Medicinal Chemistry|March 8, 2024
Immunotherapy of Human Melanoma: Past, Present, FutureKeywan Mortezaee, Jamal Majidpoor
Journal of Cellular Biochemistry|September 28, 2018
Cancer-associated fibroblasts: Secretions, interactions, and therapyBagher Farhood, Masoud Najafi, Keywan Mortezaee
Medical Oncology (Northwood, London, England)|September 7, 2022
Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updatedKeywan Mortezaee, Jamal Majidpoor, Ebrahim Kharazinejad
Life Sciences|October 20, 2022
VISTA immune regulatory effects in bypassing cancer immunotherapy: UpdatedKeywan Mortezaee, Jamal Majidpoor, Sajad Najafi
Journal of Cellular Physiology|October 15, 2018
Contribution of regulatory T cells to cancer: A reviewMasoud Najafi, Bagher Farhood, Keywan Mortezaee
International Immunopharmacology|March 18, 2023
Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: UpdatedArian Charehjoo, Jamal Majidpoor, Keywan Mortezaee
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 25, 2023
Liquid biopsy in colorectal cancerSajad Najafi, Jamal Majidpoor, Keywan Mortezaee
International Immunopharmacology|July 17, 2023
Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy - UpdatedZana Karami, Keywan Mortezaee, Jamal Majidpoor
Life Sciences|October 29, 2022
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumorsSajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Pageof 15

Showing results (51-60 of 142) with videos related to

Sort By:
Pageof 15
ACS Chemical Neuroscience|September 17, 2025
Neurotransmitters in Neural Circuits and Neurological DiseasesAmir Gholami, Keywan Mortezaee
Current Medicinal Chemistry|March 8, 2024
Immunotherapy of Human Melanoma: Past, Present, FutureKeywan Mortezaee, Jamal Majidpoor
Journal of Cellular Biochemistry|September 28, 2018
Cancer-associated fibroblasts: Secretions, interactions, and therapyBagher Farhood, Masoud Najafi, Keywan Mortezaee
Medical Oncology (Northwood, London, England)|September 7, 2022
Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updatedKeywan Mortezaee, Jamal Majidpoor, Ebrahim Kharazinejad
Life Sciences|October 20, 2022
VISTA immune regulatory effects in bypassing cancer immunotherapy: UpdatedKeywan Mortezaee, Jamal Majidpoor, Sajad Najafi
Journal of Cellular Physiology|October 15, 2018
Contribution of regulatory T cells to cancer: A reviewMasoud Najafi, Bagher Farhood, Keywan Mortezaee
International Immunopharmacology|March 18, 2023
Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: UpdatedArian Charehjoo, Jamal Majidpoor, Keywan Mortezaee
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 25, 2023
Liquid biopsy in colorectal cancerSajad Najafi, Jamal Majidpoor, Keywan Mortezaee
International Immunopharmacology|July 17, 2023
Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy - UpdatedZana Karami, Keywan Mortezaee, Jamal Majidpoor
Life Sciences|October 29, 2022
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumorsSajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Pageof 15